drug · small molecule

XPOVIO

updated 3mo ago

by $KPTI Karyopharm Therapeutics Inc.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 3

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 29 investigational indications.

targets

Exportin-1

all catalysts(0)

nothing on the calendar yet

Trials studying XPOVIO

phase2Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphomaactive not recruitingn=129
phase3A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphomaactive not recruitingn=501
phase1Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myelomarecruitingn=20
phase2Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myelomarecruitingn=62
phase3Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myelomanot yet recruitingn=260
phase3Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinomarecruitingn=276
phase3Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]completedn=263
phase3Study of Selinexor in Combination With Ruxolitinib in Myelofibrosisactive not recruitingn=353

more trials →

News(1)

Karyopharm shares crater on second Phase 3 flop for Xpovio in endometrial cancer
Karyopharm’s stock has plummeted after its second attempt to expand its blood cancer medicine Xpovio into endometrial cancer fell short. Late Thursday, the company reported that its latest trial, c…
endpoints · 17d ago

brand

XPOVIO

trade names

Nexpovio, Xpovio

generic

SELINEXOR

MOA

12.1 Mechanism of Action In nonclinical studies, selinexor reversibly inhibits nuclear export of tumor suppressor proteins (TSPs), growth regulators, and mRNAs of oncogenic proteins by blocking exportin 1 (XPO1). XPO1 inhibition by selinexor leads to accumulation of TSPs in the nucleus and reductions in several oncoproteins, such as c-myc and cyclin D1, cell cycle arrest, and apoptosis of cancer cells. Selinexor demonstrated pro-apoptotic activity in vitro in multiple myeloma cells and showed anti-tumor activity in murine xenograft models of multiple myeloma and diffuse large B cell lymphoma. The combination of selinexor and dexamethasone or bortezomib demonstrated synergistic cytotoxic effects in multiple myeloma in vitro and increased anti-tumor activity in murine xenograft multiple myeloma models in vivo, including those resistant to proteasome inhibitors.

indication

1 INDICATIONS AND USAGE XPOVIO is a nuclear export inhibitor indicated: In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy ( 1.1 ). In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody ( 1.1 ). For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s) ( 1.2 ). 1.1 Multiple Myeloma XPOVIO in combination with bortezomib and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. XPOVIO in combination with dexamethasone is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. 1.2 Diffuse Large B-Cell Lymphoma XPOVIO is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy. This indication is approved under accelerated approval based on response rate [see Clinical Studies ( 14.2 )] . Continued approval for this indication may be contingent upon verification and description

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 6m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

News(1)

Karyopharm shares crater on second Phase 3 flop for Xpovio in endometrial cancer

Karyopharm’s stock has plummeted after its second attempt to expand its blood cancer medicine Xpovio into endometrial cancer fell short. Late Thursday, the company reported that its latest trial, c…

endpoints · 17d ago

XPOVIO

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying XPOVIO

News(1)

Report a data issue

comments(0)

XPOVIO

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying XPOVIO

News(1)

Report a data issue

comments(0)